Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074 on ClinicalTrials.gov · last registry update 2021-07-15

Finished 13 July 2020, after enrolling 109 people. Primary outcome, as filed: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs). semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Gilead Sciences
Sponsor type: Industry
Enrollment: 109
Started: 2019-07-29
Primary completion: 2020-07-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

Conditions studied

Nonalcoholic Steatohepatitis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.